Follow Feed 커뮤니티에서 거래자 및 투자자와 연결하세요.
포괄적인 옵션 데이터를 탐색하고 옵션 흐름으로 고급 필터를 사용하세요.
터미널 모니터로 주식 및 자산 관심 목록을 구성하고 모니터링하세요.
Abstract was presented by TIGeR-PaC Phase III clinical trial Investigator, Paula Novelli, MD, from the University of Pittsburgh Medical Center...
Oncology's Best Minds Set to Meet at Upcoming 2025 ASCO Gastrointestinal Cancers Symposium PR...
Two additional abstracts have been accepted to be presented at upcoming prestigious industry conferences, SIO 2025 and SSO 2025 The accepted...
RenovoRx Holds a Strong IP Portfolio with 18 Issued Patents and 13 Pending Patents as it Moves Forward with Commercialization and Clinical Trial...
TIGeR-PaC is Evaluating the TAMP™ (Trans-Arterial Micro-Perfusion) Therapy Platform for the Treatment of...
LOS ALTOS, Calif., Dec. 10, 2024 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq:...
Over Ten Medical Institutions Nationwide have Initiated RenovoCath Purchase Process, Further Accelerating...
The Northwell Health Cancer Institute is the Most Recent Clinical Site to Join the TIGeR-PaC Study, and...
Near-Term Revenue Potential with Commercialization Plan for FDA-Cleared RenovoCath® Delivery System in Both...
귀하가 조회한 주식이 이 박스에 나타나며 쉽게 최근 시세로 돌아갈 수 있습니다.
도움 및 지원받기: kr-support@advfn.com
ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관
광고 없는 경험을 위해 가입하세요
지금 사용해 보세요
광고 유지